**Abstract**

**Objective**: Serotonin syndrome is a serious adverse reaction characterized by a cluster of dose-related adverse effects that are due to increase serotonin (5-HT) concentrations in the central nervous system. Dextromethorphan (DM) has complex neuropharmacologic effects. It has been reported that high doses of DM produce serotonin syndrome in both human and animal models. 5-HT receptor activation is thought to contribute mainly to the serotonin syndrome in mice. In the present study, we have asked whether 5-HT receptor is involved in serotonin syndrome induced by DM.

**Methods**: Mice were treated with WAY100635, a 5-HT1A receptor antagonist, or MDL11939, a 5-HT2A receptor antagonist, 30 min before DM administration. Scores of serotonin syndrome (i.e. reciprocal forepaw treading, lateral head-weaving, hind-limb abduction, tremor, Straub tail and flat body posture) were assessed during 30 min after DM. In addition, rectal temperature was measured 30 min after DM. Serotonin levels and 5-HT1A receptor mRNA expression were examined in the hypothalamus 2 h after DM.

**Results**: A high dose of DM significantly produced serotonin syndrome in mice. In addition, treatment with DM resulted in a significant increase in 5-HT1A receptor mRNA expression but not that of 5-HT2A receptor in the hypothalamus of mice. Furthermore, WAY100635, but not MDL11939, significantly attenuated increases in hypothalamic serotonin level, serotonergic behaviors and hypothermia induced by DM.

**Conclusion**: Up-regulation of 5-HT1A receptor is essential for serotonin syndrome induced by DM in mice \[This study was supported by a grant (14182MFDS979) from the Korea Food and Drug Administration, Republic of Korea\].
